InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,460.48
(
-0.41%
)
US TECH 100
19,181.60
(
-0.43%
)
Dow Jones
39,118.86
(
-0.12%
)
Brent Oil
84.85
(
0.00%
)
Bitcoin
62,224.50
(
2.19%
)
Post# of 48252
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

PennystockID2017

Send PM Follow Ignore
Followers 310
Posts 32161
Boards Moderated 0
Alias Born 11/10/2011

PennystockID2017

Re: None

Saturday, 01/06/2018 10:10:19 PM

Saturday, January 06, 2018 10:10:19 PM

Post# of 48252
The CEO of Life Clips is also a director of this company.
Kalytera is developing a clinical-stage cannabidiol (“CBD”) medicine to prevent and treat Graft versus Host Disease (“GvHD”). GvHD is a multisystem disorder that is a common, life-threatening complication of hematopoietic stem cell transplant (“HCT”) procedures. GvHD occurs when the transplanted donor cells attack the patient’s organs, including the skin, gastrointestinal tract, liver, lungs, and eyes. GvHD is associated with acute and chronic illness, infections, disability, reduced quality of life, and death. Learn more >>
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up